Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) SVP Brendan M. O'malley sold 17,428 shares of Abeona Therapeutics stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total value of $102,128.08. Following the transaction, the senior vice president owned 360,817 shares in the company, valued at approximately $2,114,387.62. This represents a 4.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Abeona Therapeutics Stock Down 1.9%
Shares of NASDAQ:ABEO traded down $0.11 during midday trading on Friday, reaching $5.74. The company had a trading volume of 774,254 shares, compared to its average volume of 701,588. The company has a quick ratio of 4.90, a current ratio of 4.90 and a debt-to-equity ratio of 0.27. The business's 50 day moving average price is $6.01 and its 200 day moving average price is $5.57. The stock has a market cap of $293.64 million, a PE ratio of -4.52 and a beta of 1.51. Abeona Therapeutics Inc. has a 1-year low of $3.93 and a 1-year high of $7.32.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.11. Research analysts forecast that Abeona Therapeutics Inc. will post -1.16 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have recently commented on ABEO. HC Wainwright boosted their price target on Abeona Therapeutics from $15.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, April 30th. Oppenheimer initiated coverage on Abeona Therapeutics in a research report on Monday, June 2nd. They issued an "outperform" rating and a $19.00 target price on the stock. Stifel Nicolaus lowered their target price on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Alliance Global Partners reaffirmed a "buy" rating on shares of Abeona Therapeutics in a research report on Thursday, May 15th. Finally, Wall Street Zen downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $19.25.
Read Our Latest Research Report on ABEO
Hedge Funds Weigh In On Abeona Therapeutics
A number of institutional investors have recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. increased its position in Abeona Therapeutics by 20.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company's stock worth $21,736,000 after buying an additional 652,366 shares during the last quarter. Western Standard LLC increased its position in Abeona Therapeutics by 22.8% during the fourth quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company's stock worth $11,610,000 after buying an additional 386,321 shares during the last quarter. 683 Capital Management LLC increased its position in Abeona Therapeutics by 17.3% during the fourth quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company's stock worth $4,411,000 after buying an additional 116,845 shares during the last quarter. Newtyn Management LLC increased its position in Abeona Therapeutics by 26.3% during the first quarter. Newtyn Management LLC now owns 480,000 shares of the biopharmaceutical company's stock worth $2,285,000 after buying an additional 100,000 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Abeona Therapeutics by 16.7% during the fourth quarter. Bank of America Corp DE now owns 264,439 shares of the biopharmaceutical company's stock worth $1,473,000 after buying an additional 37,774 shares during the last quarter. Institutional investors and hedge funds own 80.56% of the company's stock.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
See Also
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
